Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore : the DIALS study

Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore : the DIALS study

Background: To determine the frequency of persistent disease activity following 3 loading doses of anti- vascular endothelial growth factor (VEGF) agents, and the anatomic and demographic predictors of early persistent disease activity among patients with neovascular age-related macular degeneration...

Full description

Bibliographic Details
Main Authors:	Tan, Colin Siang Hui, Lim, Louis W., Ngo, Wei Kiong, Pannirselvam, Pandiyan, See, Clarence, Chee, Wai Kitt, Saxena, Nakul
Other Authors:	Lee Kong Chian School of Medicine (LKCMedicine)
Format:	Journal Article
Language:	English
Published:	2021
Subjects:	Science::Medicine Anti-VEGF Neovascular Age Related Macular Degeneration
Online Access:	https://hdl.handle.net/10356/146305

Similar Items

Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study
by: Colin S. Tan, et al.
Published: (2020-08-01)

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
by: Prem Patel, et al.
Published: (2021-05-01)

One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
by: Coney JM, et al.
Published: (2023-11-01)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
by: Henrik Faatz, et al.
Published: (2022-11-01)

Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER
by: Ramin Tadayoni, et al.
Published: (2023-06-01)

Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME
by: Fernando M Penha, et al.
Published: (2024-01-01)

The Efficacy and Safety of Brolucizumab for the Treatment of nAMD: A Systematic Review and Meta-Analysis
by: Junlan Chuan, et al.
Published: (2022-05-01)

Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
by: Tan CS, et al.
Published: (2022-03-01)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
by: Nicola Ferrante, et al.
Published: (2022-04-01)

PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections
by: Touka Banaee, et al.
Published: (2021-05-01)

Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
by: Carolina Arruabarrena, et al.
Published: (2021-07-01)

Neovascular Remodeling and Subretinal Fibrosis as Biomarkers for Predicting Incomplete Response to Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration
by: Jing Wu, et al.
Published: (2022-04-01)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
by: Greggory M. Gahn, et al.
Published: (2018-03-01)

Angiogenin, FGF-α, and IL-36β have higher expression levels in aqueous humor of nAMD patients in comparison to cataract patients
by: Kailin Chen, et al.
Published: (2020-10-01)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
by: Praveen Yerramothu
Published: (2018-07-01)

Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization
by: Yingbin Fu, et al.
Published: (2024-02-01)

Strongest Correlation Between Contrast Sensitivity and Morphological Characteristics in Bilateral nAMD
by: Laura Hoffmann, et al.
Published: (2021-01-01)

Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration
by: Pelin Kıyat, et al.
Published: (2021-06-01)

Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab
by: Lucia Gonzalez-Buendia, et al.
Published: (2017-08-01)

Comparison of morphometric changes in the chorioretinal complex after anti-VEGF treatment in patients with pathologic myopia versus those with neovascular age-related macular degeneration
by: O.M. Blavatska, et al.
Published: (2018-02-01)

Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration
by: Oyuna S. Kozhevnikova, et al.
Published: (2022-07-01)

Delaying anti-VEGF therapy during the COVID-19 pandemic: long-term impact on visual outcomes in patients with neovascular age-related macular degeneration
by: Marco Nassisi, et al.
Published: (2023-04-01)

Prediction of the short-term efficacy of anti-VEGF therapy for neovascular age-related macular degeneration using optical coherence tomography angiography
by: Huixun Jia, et al.
Published: (2022-05-01)

Anti-vascular endothelial growth factor in neovascular age-related macular degeneration – a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems
by: Robert P. Finger, et al.
Published: (2020-07-01)

Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study
by: Jin Jing, et al.
Published: (2018-07-01)

Targeted therapy in age-related macular degeneration (AMD)
by: Klaudia Daria Szumna, et al.
Published: (2020-03-01)

Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration
by: Avaylon J, et al.
Published: (2020-05-01)

COMPARISON OF CLINICAL AND REAL-LIFE TRiaLS OF THE EFFECTIVENESS OF ANTI-VEGF THERAPY FOR age-related macular degeneration
by: M. V. Budzinskaya, et al.
Published: (2019-02-01)

Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab
by: Pasquale Viggiano, et al.
Published: (2022-09-01)

Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration
by: Reem H. ElSheikh, et al.
Published: (2022-11-01)

Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis
by: Pengxiang Zhou, et al.
Published: (2021-10-01)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
by: Kabanarou SA, et al.
Published: (2017-05-01)

Determination of Vascular Endothelial Growth Factor-B Concentrations in Aqueous Humor and Plasma of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy Patients Before and After Anti-VEGF Therapy
by: Huiying Zhou, et al.
Published: (2022-12-01)

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
by: Aira Sarkar, et al.
Published: (2021-09-01)

A novel small molecule anti-VEGF drug Brolucizumab in the treatment of neovascular age-related macular degeneration
by: Tong Wu, et al.
Published: (2022-05-01)

Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy – a systematic approach to identify and characterize data sources
by: Vincent Daien, et al.
Published: (2019-10-01)

Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration
by: Benjamin Ng, et al.
Published: (2024-01-01)

Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence
by: Chakraborty D, et al.
Published: (2023-04-01)

Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study
by: Solomon SD, et al.
Published: (2021-08-01)

Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01)